First Randomized Controlled Trial Shows Promise of a Ketogenic Diet in Psychotic Disorders

A first randomized controlled trial reports that a ketogenic diet improves metabolic markers and shows early promise for reducing symptoms in bipolar disorder and schizophrenia. The research is partly funded by Baszucki Group, but without disclosed efficacy magnitudes or statistical results, near-term investable impact is likely limited.

Analysis

A first randomized controlled trial reports that a ketogenic diet improves metabolic markers and shows early promise for reducing symptoms in bipolar disorder and schizophrenia. The research is partly funded by Baszucki Group, but without disclosed efficacy magnitudes or statistical results, near-term investable impact is likely limited.